Search Bar & Filters
Found 6 Actively Recruiting clinical trials
Actively Recruiting
Researchers are conducting a noninterventional, prospective observational study in Canada to monitor participants with Alzheimers Disease who are treated with LEQEMBI during routine clinical practice. The study aims to describe the occurrence and severity of known side effects, including brain imaging abnormalities and intracerebral hemorrhages, and analyze these according to genetic factors, other medications, and baseline brain scans. Additionally, the study will observe the progression of Alzheimers Disease and identify any previously unknown side effects related to LEQEMBI. Participants in this registry study are those prescribed LEQEMBI and will be observed without any experimental treatment or intervention. The study collects data on drug use, adverse events, disease progression, and the effectiveness of safety measures over a period of up to three years. There is no active treatment administered by the study, and information is gathered during routine medical care. During the study, participants will have their health monitored through regular clinical practice assessments. Researchers will track side effects, disease progression, treatment duration, and drug utilization. Data on serious adverse reactions, treatment discontinuations, and deaths within 30 days of stopping LEQEMBI will also be collected. The study will last up to three years with ongoing observation to evaluate the safety and outcomes associated with LEQEMBI use.
Actively Recruiting
Atrial Fibrillation AF affects many individuals and raises the risk of stroke, which can severely impact daily functions such as speaking, walking, and self-care, and can be fatal. Blood clots forming in the heart due to AF can travel to the brain and cause strokes. Blood thinners, or anticoagulants, help reduce this risk by preventing clot formation. While warfarin has been widely used, newer direct oral anticoagulants DOACs like rivaroxaban and apixaban offer alternatives without the need for regular blood tests or dietary restrictions. However, there has been no direct comparison between these two newer drugs to assess their relative safety. This research compares the safety of apixaban taken twice daily and rivaroxaban taken once daily over 12 months in patients with non-valvular atrial fibrillation. Doses may be adjusted based on age, weight, kidney function, or creatinine clearance. Both groups receive treatment orally, with regular monitoring of kidney function at the start and annually. The trial aims to measure bleeding events and other outcomes during the treatment period. Participants will be followed for one year, with researchers monitoring bleeding complications, stroke or transient ischemic attack events, medication adherence, mortality, and cost-effectiveness. These assessments include clinical evaluations and tracking of any significant bleeding episodes. This trial will help inform treatment choices by comparing the safety profiles of these two anticoagulants for stroke prevention in AF.
Actively Recruiting
Researchers are evaluating efgartigimod as a replacement for intravenous immunoglobulin IVIG therapy in patients with stable, acetylcholine receptor antibody positive myasthenia gravis who depend on regular IVIG treatments. The study aims to determine if efgartigimod is as effective or not worse than IVIG, to assess patient preference between the two treatments, and to evaluate the safety and tolerability of efgartigimod given over six months. Participants will stop IVIG one week before starting the study. Efgartigimod will be given as a one-hour intravenous infusion at a dose of 10 mgkg up to 1200 mg once weekly for four weeks, followed by a four-week break. This cycle will repeat four times until week 24. After the last treatment cycle, participants will be observed for two weeks before the study ends at week 26. Throughout the 26 weeks, participants will have weekly evaluations of their myasthenia gravis symptoms using MG-ADL and MGQOL assessments. Researchers will monitor the sustained improvement in MG-ADL scores for at least four consecutive weeks as the primary outcome. Secondary outcomes include changes in QMG scores, quality of life measures, and the number of patients continuing efgartigimod at study end. Safety and tolerability of the treatment will also be closely monitored.
Actively Recruiting
Healthy Volunteer
Researchers are studying whether a wearable robotic exoskeleton can improve mobility, balance, and walking in healthy older adults and people living with Parkinsons disease. These groups face a high risk of falls and mobility challenges due to age-related or disease-related movement impairments. The study aims to understand the immediate effects of the exoskeleton on walking and balance, identify who benefits most, and explore how users feel about using this technology in daily life. The study involves two laboratory sessions held 2 to 4 days apart. In the first session, participants undergo clinical assessments, are fitted with the exoskeleton, and take part in interviews about their expectations and perceptions. In the second session, they perform mobility tasks such as walking and standing with and without the exoskeleton under six different conditions, including various levels of assistance and no assistance. The order of assistance levels is randomized. Movement is measured using wearable sensors to gather detailed walking data. Participants will be involved in clinical tests of balance, gait, physical activity, mood, fatigue, and cognition, along with interviews before and after exoskeleton use. Mobility performance will be evaluated through timed walking and standing tests, and walking variability will be monitored using sensors. For those with Parkinsons, assessments occur during their optimal medication effect. The study measures immediate changes in walking speed, balance, and sit-to-stand times, as well as user acceptability of the device. Participation spans two sessions over about a week, with all data collected in a controlled lab setting.
Actively Recruiting
This research compares two different post-operative salvage radiotherapy schedules for men with recurrent prostate cancer after surgery who have detectable PSA levels. The goal is to determine if a shorter treatment plan is as safe and effective as the standard longer schedule. This study is important because cancer can return in many high-risk patients after prostate surgery, and the best radiotherapy approach, including treatment length and pelvic area coverage, remains under study. Participants will receive either the standard radiotherapy with 25 sessions over about 5 weeks delivering 62.5 Gy to the prostate bed and 45 Gy to the pelvis, or a shorter schedule with 20 sessions over about 4 weeks delivering 52.5 Gy to the prostate bed and 43 Gy to the pelvis. Both groups may also receive hormone therapy Androgen Deprivation Therapy for 6 to 24 months, depending on the doctors discretion. Some patients with pelvic nodal disease may receive additional medications for 24 months following a specific protocol. During the study, participants will be monitored for side effects related to urinary and bowel health for up to 24 months after radiotherapy. Researchers will also assess cancer control through PSA levels and disease spread, survival rates, and quality of life using urinary, bowel, and sexual health questionnaires. Follow-up evaluations will continue for up to 10 years, with assessments at regular intervals to understand long-term outcomes and safety. The entire study is expected to last about 12 years, including 2 years for enrollment and 10 years of follow-up.
Actively Recruiting
Researchers are evaluating the impact of repetitive Transcranial Magnetic Stimulation rTMS on walking ability in people with Multiple Sclerosis MS who have spastic paraparesis and moderate walking disability. The study aims to measure changes in overall disability, walking endurance, quality of life, and brain activity patterns using EEG in patients with MS. This interventional trial is led by Clinique Neuro-Outaouais and uses a randomized, parallel design with triple masking. Participants will receive rTMS treatment using magnetic pulses targeting specific brain areas. The active treatment group will get 100% magnetic pulse intensity, while the comparison group will receive sham rTMS at 10% intensity. The treatment is scheduled daily, five times a week, for 6 consecutive weeks. After a 6-week break, all participants will then receive active rTMS treatment for another 6 weeks. During the study, participants will be assessed using walking tests including the Timed 25-Foot Walk Test T25FWT and the Six Minute Walk Test 6MWT, along with quality of life questionnaires MSQoL. The study will also monitor EEG parameters to assess neural synchrony. The primary outcome will be measured at 18 weeks, with secondary outcomes assessed at 12 weeks. Total participation will cover the treatment and evaluation periods, with safety and compliance monitored throughout.